Pharma Mar Dividends and Buybacks
Dividend criteria checks 0/6
Pharma Mar is a dividend paying company with a current yield of 0.83%.
Key information
0.8%
Dividend yield
1.0%
Buyback Yield
| Total Shareholder Yield | 1.8% |
| Future Dividend Yield | 0.8% |
| Dividend Growth | 10.7% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | €0.650 |
| Payout ratio | 1,833% |
Recent dividend and buyback updates
Recent updates
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Oct 16
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Jul 28Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Jun 01Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
May 28Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 03Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 28We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Mar 08Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Mar 05Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Sep 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%
May 04Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding
Mar 16Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly
Sep 08News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts
Aug 03Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock
May 31Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
May 10Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 08Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years
Jan 14Is Pharma Mar (BME:PHM) A Risky Investment?
Nov 19Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, PHM has been paying a dividend for less than 10 years.
Growing Dividend: PHM's dividend payments have increased, but the company has only paid a dividend for 5 years.
Dividend Yield vs Market
| Pharma Mar Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (PHM) | 0.8% |
| Market Bottom 25% (ES) | 2.3% |
| Market Top 25% (ES) | 5.6% |
| Industry Average (Biotechs) | 1.6% |
| Analyst forecast (PHM) (up to 3 years) | 0.8% |
Notable Dividend: PHM's dividend (0.83%) isn’t notable compared to the bottom 25% of dividend payers in the Spanish market (2.35%).
High Dividend: PHM's dividend (0.83%) is low compared to the top 25% of dividend payers in the Spanish market (5.64%).
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (1832.8%), PHM's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: PHM is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 14:07 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharma Mar, S.A. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Guilherme Sampaio | Banco BPI, S.A. |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Keay Nakae | Chardan Capital Markets, LLC |